Evidence-based Care and Therapeutic Updates to Reduce the Risk for Rapid Progression and Recurrence of Hepatic Encephalopathy

 

 

On-demand CME/CE webcast previously recorded from the September 25, 2021, Hospital Medicine Summit

PROGRAM OVERVIEW

Hepatic encephalopathy (HE) is a brain dysfunction caused by liver insufficiency and/or portosystemic shunting. It manifests as subneurological or psychiatric abnormalities that range in severity from subclinical alterations to coma. In the absence of effective treatment, HE is associated with a high risk of recurrence and hospitalization, and while significant advances in care have occurred over the past decade, patients hospitalized with HE continue to have high mortality risk. Both the AASLD/EASL practice guidelines and ISHEN consensus statements provide detailed, evidence-based recommendations for the prevention of acute episode recurrence and strategies for improving the care of patients with HE. This program is targeted at providing hospital-based clinicians with the knowledge and skills required to ensure that current practice is aligned with these recommendations.

Faculty Speaker

Jasmohan S. Bajaj, MBBS, MD, MS, FACG
Professor of Medicine
Division of Gastroenterology, Hepatology, and Nutrition
Virginia Commonwealth University and McGuire VA Medical Center
Richmond, Virginia

 

Release date: November 15, 2021
Expiration date: November 15, 2022
Estimated time to complete activity: 1 hour

 

 TARGET AUDIENCE

This educational activity has been designed to meet the needs of physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists who practice in hospital, internal medicine, and chronic-care settings.

 LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Describe a plan of care for patients hospitalized with HE that is consistent with updated evidence-based recommendations
  • Review the efficacy and safety of therapies for treatment of acute episodes of overt HE and prevention of their recurrence
  • Identify crucial components of a transitional care plan to prevent future hospitalizations among patients with HE
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity. During the period of November 15, 2021, through November 15, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%. Pharmacists must check the CPE monitor for their credits within 60 days of the activity.

MEDIA

Internet

PHYSICIAN CONTINUING EDUCATION

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Numbers – 0530-9999-21-289-H01-P.)

This is a knowledge-based activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.

For information about ACPE or ANCC accreditation of this activity, please contact Global at (303) 395-1782 or cme@globaleducationgroup.com.

SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLOSURE OF CONFLICTS OF INTEREST (COI)

Integrity Continuing Education and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

FACULTY DISCLOSURES

Jasmohan S. Bajaj, MBBS, MD, MS, FACG
Consulting Fees: Norgine
Contracted Research: Cosmo Pharmaceuticals, Grifols, Sequana Medical, and Valeant Pharmaceuticals

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Liddy Knight, Kim Rodriguez, Rhys Williams, RN, MSN, FNP, Maria Rovere, MTSC, and Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.
This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from Salix Pharmaceuticals.

 

Continue to Pretest